Study of nonenzymatic antioxidants in schizophrenic patients

Hemant S. Dahake, Suresh Ghangle, Jayesh Warade, Yogesh Pawade, Gaurav S. Kansara


Background: Schizophrenia is one of the most debilitating psychiatric disorders. There is now substantial evidence of increased free radical–mediated damage in schizophrenia. These mechanisms are critical role in etiopathogenesis of schizophrenia. The potential toxicity of reactive oxygen species (ROS) is counteracted by a large number of cytoprotective enzymes and nonenzymatic anti-oxidants. Endogenous substances like albumin, bilirubin and uric acid play very important defensive role against reactive oxygen species (ROS) produced in our body. The present study was undertaken to study nonenzymatic antioxidants i.e. serum albumin, bilirubin and uric acid in first episode and chronic schizophrenic patients.

Methods: 50 patients of first episode schizophrenia and 50 patients of chronic schizophrenia were included in the study. 50 numbers of age and sex matched healthy and apparently normal controls were also selected for study. Blood samples were drawn and analysed for albumin, bilirubin and uric acid from all participants.

Results: The study shows significant decrease in serum albumin, bilirubin and uric acid levels in both first episode schizophrenics and chronic schizophrenic patients as compared to controls. When we compared levels of these parameters in first episode schizophrenics and chronic schizophrenics, we did not find significant difference.

Conclusions: Findings in our study is suggesting that decrease in the levels of nonenzymatic antioxidants occurs in attempting neutralization of ROS in schizophrenics. This study supports the defensive role of nonenzymatic antioxidants against ROS in our body.


Schizophrenia, Antioxidants, Albumin, Bilirubin, Uric Acid

Full Text:



Stahl SM. Essential psychopharmacology neuroscientific basis and practical application. 2nd ed. Cambridge University Press; 2004:365-458.

Victor IR. Mental disorders, In: Harrison’s principles of Internal Medicine. 16th edition. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. New Delhi: McGraw-Hill; 2005:P.2547-2561.

Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipids dysregulation and its therapeutic implications. Psychiatr Clin N Am. 2003;26:85-102.

Marshall WJ and Bangret SK. In: clinical biochemistry-metabolic and clinical aspects, Published: Churchill Livingstone, Medical Division of Pearson Professional Ltd;1995:223-225, 621-640, 765-777.

Vendemiale G, Grattagliano I, Altomare E. An update on the role of free radicals and antioxidant defense in human disease. Ind J Clin Lab Res. 1999;29:49-55.

American psychiatric association DSM-IV.DSM-IV diagnostic criteria for schizophrenia. Diagnostic and statistical manual of mental disorders. 4th ed. Washington; 1994:273-315.

Ustundag B, Atmaca M, Kirtas O. Total antioxidant response in patients with schizophrenia. Psych Clin Neurosci. 2006;60(4):458-64.

Uma Devi P, Chinnaswamy P. Oxidative injury and enzymic antioxidant misbalance in schizophrenics with positive, negative and cognitive symptoms. African J Biochem Res. 2008;2(4):092-7.

Reddy R, Keshavan M,Yao JK. Reduced plasma antioxidants in first episode patients with schizophrenia. Schizophrenia Res. 2003;62:205-12.

Gutteridge JM. Antioxidant properties of the proteins caeruloplasmin, albumin and transferrin. A study of their activity in serum and synovial fluid from patients with rheumatoid arthritis. Biochim Biophys Acta. 1986;869:119-27.

Processed Foods. In: Frankel EN. Lipid Oxidation. 2nd Ed. Dundee Scotland. The Oily Press; 2012:307-317.

Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, Lee CU. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology. 2004;50:54-6.

Tiao-Lai H. Decreased serum albumin levels in Taiwanese patients with schizophrenia. Psych Clin Neurosci. 2002;56:627-30.

Yao JK, Reddy R, Van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psych Res. 2000;97(2-3):137-51.

Umadevi P, Murugan S. Biochemical derangements in patients with schizophrenia: case-control study. J Clin Diagn Res. 2008;2(4):1001-8.

Iwao Y, Ankaru M, Hiraike M, Kawai K, Nakajou K, Kai T et al. The structural and pharmacokinetic properties of oxidized human albumin, advanced oxidation protein products (AOPP). Drug Metab Pharmacokinet. 2006;21(2):140-6.

Anraku M, Kragh-Hansen U, Kawai K, Maruyama T, Yamasaki Y, Takakura Y, et al. Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo. Pharmaceut Res. 2003;20(4):684-92.

Stocker R, Yamamoto Y, Mc Donagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiologic importance. Sci. 1987;235:1043-46.

Frei B, Stocker R, Ames BN. Antioxidant defences and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA. 1988;85:9748-52.

Lleusy SF, Tomaro ML. Hemeoxygenase and oxidative stress evidence of involvement of bilirubin as physiological antioxidant against oxidative damage. Biochemica et Biophysica Acta. 1994;1223:9-14.

Garcia-Unzueta MT, Herran A, Sierra-Biddle D, Amado JA, Vázquez-Barquero JL, Alvarez C. Alterations of liver function test in patients treated with antipsychotics. J Clin Laboratory Anal. 2003;17(6):216-8.

Yasukawa R, Miyaoka T, Yasuda H, Hayashida M, Inagaki T, Horiguch J. Increased urinary excretion of biopyrrins, oxidative metabolites of bilirubin, in patients with schizophrenia. Psych Res. 2007;153(2):203-7.

Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defence in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858-62.

Becker BF. Towards the physiological function of uric acid. Free Radical Biol Med. 1993;14:615-31.

Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J. 1986;235:747-54.

Yao JK, Reddy R, Van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psych Res. 1998;80(1):29-39.